This article was originally published in The Tan Sheet
Executive SummaryAdams Respiratory Therapeutics acquired the Humibid trademark from Cornerstone BioPharma in February 2005, but not the Humibid line as reported in the Nov. 13 issue of "The Tan Sheet." The article incorrectly described Adams CEO Michael Valentino's comments as implying that forecast data indicate harsh weather this winter season...
You may also be interested in...
While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.
Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.
First Circuit reverses dismissal of direct purchasers' suit alleging improper listing of patent on device drive mechanism delayed competition; district court to decide if this constitutes antitrust violation.